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Background: To face the current COVID-19 pandemic, diagnostic tools are essential. It is recommended to
use real-time RT-PCR for RNA viruses in order (a) to perform a rapid and accurate diagnostic, (b) to guide
patient care and management and (c) to guide epidemiological strategies. Further studies are warranted
to define the role of serological diagnosis and a possible correlation between serological response and
prognosis.
Objectives: The aim was to guide clinical microbiologists in the use of these diagnostic tests and clini-
cians in the interpretation of their results.
Sources: A search of literature was performed through PubMed and Google Scholar using the keywords
SARS-CoV-2, SARS-CoV-2 molecular diagnosis, SARS-CoV-2 immune response, SARS-CoV-2 serology/
antibody testing, coronavirus diagnosis.
Content: The present review discusses performances, limitations and use of current and future diag-
nostic tests for SARS-CoV-2.
Implications: Real-time RT-PCR remains the reference method for diagnosis of SARS-CoV-2 infection. On
the other hand, notwithstanding its varying sensitivity according to the time of infection, serology
represents a valid asset (a) to try to solve possible discrepancies between a highly suggestive clinical and
radiological presentation and negative RT-PCR, (b) to solve discrepancies between different PCR assays
and (c) for epidemiological purposes. G. Caruana, Clin Microbiol Infect 2020;26:1178
© 2020 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In December 2019, numerous cases of pneumonia of unknown
aetiology were reported inWuhan (China) [1]. In January, the novel
causative virus named SARS-CoV-2 was identified, which spread to
other Chinese regions and to other countries, causing a world
pandemic [2,3]. The clinical presentation of this disease, named
coronavirus disease 2019 (COVID-19), varied from asymptomatic or
mild flu-like symptoms to severe bilateral pneumonia with acute
respiratory distress and death. A rapid replication of the viruscrobiologie, Departement de
tre Hospitalier Universitaire
ugnon 48, CH-1011, Lausanne,
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).within the first 24 hr from the infection and the relatively high
(about 3) reproduction number were described [4].
The available viral genome sequences allowed to soon recognize
the close relationship between SARS-CoV-2 and SARS-CoV-1, the
causative pathogen of the 2002e2004 outbreak, presenting with
severe acute respiratory syndrome (SARS).
Both viruses belong to the Coronaviridae family. They are
characterized by a single-stranded 30 kb positive-sense RNA and
enveloped spherical virions of about 160 nm. The unusual large size
of their genome leaves these viruses enough space to rearrange
their genes (recombination), thus donating them some genomic
plasticity [5]. Furthermore, RNA biosynthesis seems to use a virus-
specific template switch, which results in transcription of sub-
genomic mRNAs and eventually leading to homologous RNA
recombination [5]. Nevertheless, by encoding a 30-50 exoribonu-
clease within non-structural protein 14 (nsp14-ExoN), which is
required for high-fidelity replication, the mutation capacity ofof Clinical Microbiology and Infectious Diseases. This is an open access article under
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allowed Coronaviridae to acquire a rich strains biodiversity and the
ability to jump species, which had already caused previous zoonotic
outbreaks, such as for MERS-CoV and SARS-CoV [7e9].
Starting from observed similarities in a short region of RdRp
gene between SARS-CoV-2 and a bat coronavirus (BatCoVRaTG13),
further sequences were identified to be 96% identical at the whole-
genome level, corroborating the hypothesis of animals to humans
spillover [10].
As of 3 June, more than 6 million cases of COVID-19 have been
declared, including more than 380 000 deaths [11]. Because of the
rapid and fatal spread of the pandemic, the research on develop-
ment of diagnostic tests was set as a priority for infection control
measures and patient care.
The present review summarizes performances and limitations
of diagnostic tests to help clinicians in the interpretation of the
results and clinical management.Diagnostic tests for SARS-CoV-2
Nucleic acid amplification tests (NAATs)
Three of the major challenges in molecular diagnosis are (a) to
detect small amounts of viral RNA for reducing the number of false
negatives, (b) to differentiate the positive signal among different
pathogens for decreasing the number of false positives and (c) to
have a large capacity, in order to quickly and correctly test a large
number of patients, while avoiding false negatives and false posi-
tives. Molecular and serological tests were previously compared
during the SARS-CoV-1 epidemic, showing an increased sensitivity
and specificity for the molecular ones. For this reason, real-time
reverse transcription polymerase chain reaction (rRT-PCR) repre-
sents the validated assay for early diagnosis in patients with sus-
pected SARS-CoV-2 infection [12].
First publications showed that diagnosis was possible by tar-
geting the spike (S) gene of the virus with a good specificity
(differentiating SARS-CoV-2 from SARS-Cov-1), but limited sensi-
tivity [10]. Sensitivity was further improvedwhen integrating other
viral-specific genes, such as RdRp/Helicase (Hel), Nucleocapside (N)
and Envelop (E) genes [13]. A comparison between all targeted
genes revealed that the best results were obtained with RdRp/Hel
genes [14], and WHO guidelines recommend the use of RdRp, E, N
and S genes in different combinations [12]. In our institution, we
introduced theWHO recommended test described by Corman et al.
(targeting the E gene, followed by confirmationwith RdRp primers)
[13] on our fully automated molecular diagnostic platform [15].
RNA extraction was performed through the MagNA Pure 96 System
(Roche, Basel, Switzerland) and the rRT-PCR was carried out on a
QuantStudio 7 system (Applied Biosystems, Waltham, USA) [15];
we observed low sensitivity of the rRT-PCR targeting the RdRp gene
due to a mismatch [16] in the primer described by Corman et al.
[13] and, since the E gene was constantly more sensitive than RdRP,
we decided, after having performed about 1000 tests, to continue
addressing the E gene only [16]. This allowed us to save reagents
and to be able to perform an increasing number of tests in a setting
of reagent shortage due to the pandemic nature of Covid-19. To
detect a possible drift due to mutations and to avoid that a mutant
strain escape our diagnostic test, we kept targeting both E and RdRp
genes once a week.
RNA extraction methods can generally be classified into (a) one
step (with the RT step and the PCR reaction in the same tube) and
(b) two-step RT-PCR (initial creation of DNA copies with RT reaction
followed by their addiction to the PCR reaction). Typically, one-step
PCR uses one reaction tube, minimizing the risk of contamination(false-positive results). On the other hand, two-step PCR allows the
cDNA sample to be archived and further testing of other genes.
As pointed out in a recent work from Pang et al. [17], there are
different RNA extraction platforms (summarized in Table 1), which
can allow sensitivity and TAT to be improved but also sometimes
increasing the costs.
Despite the good performance of the validated nucleic acid
amplification tests (NAATs), there is still a risk of false-negative
results. Most of them concern the pre-analytic setting, such as
the timing of the specimen collection (too early or too late in the
infection course, including the limit of detection due to late in-
fections with atypical manifestations), the quality of sampling
(insufficientmaterial) or type of specimens (bronchoalveolar lavage
(BAL) exhibits the highest sensitivity, followed by induced sputum,
nasopharyngeal (NP) swab, oropharyngeal (OP) swab and faeces),
and finally the sample transport (inappropriate container, exposure
to extreme temperatures, etc.) [18,19]. Further reasons decreasing
the performance of a molecular test include the ability of the virus
to mutate (changing sequence of the regions in which primers are
hybridizing), or the PCR inhibition [20], the latter being nowadays
almost insignificant (in our laboratory, we observed an inhibition in
about 0.3% of the tested samples).
With the purpose of reducing the TAT of NAATs, several rapid
microarray and sequencing solutions built on multi-RT-PCR panels
(and automated systems) have been developed [17,21]. An impor-
tant highly performing test, although expensive and not useful for a
high number of samples, is the GenXprt SARS-CoV-2 test (Cepheid,
https://www.cepheid.com), which due to its simplicity and its very
short TAT, rapidly helped patient management especially regarding
isolation procedures [22].
Finally, several manufacturers already developed other
advanced specific systems [23e28] and investigations showed their
easiness, rapidity and compatibility with automation [29,30].
Serological testing
One of the downsides of serological assays is the limited
sensitivity at an early stage, when the host has not yet developed
specific antibodies. In the specific case of SARS-CoV-2, data from
literature showed production of IgM and IgG starting after the first
week from infection and generally detectable from the second
[31e34], leaving some space for delayed antibody responses, pre-
viously associated (for MERS-CoV) with more severe disease [35].
Another conundrum is to avoid the cross-reactivity between
antibodies against different viruses, part of the same or different
families. This was a concearn since most of the human coronavi-
ruses are antigenically closely related [36], although solvable by
adding a virus neutralization test (as previously suggested byWHO
during the SARS epidemic in 2004) [37]. However, most current
serology tests exhibit a specificity greater than 98%.
Sensitivity and specificity of serological assays can also be
affected by the target antigen. As highlighted by Meyer et al., the S
protein (produced in more advanced stage of SARS-CoV-2 infec-
tion) showed lower levels of sensitivity and more specificity
(especially the S1 subunit) than the N protein [38]. We recently
observed (data not shown) that the antibodies directed against the
N protein seems to decrease earlier than the S protein; thus the
sensitivity of assays targeting only the N protein may be impaired
according to the timing of infection (Fig. 1). For this reason, we
recommend to systematically use two tests, one targeting the S
protein and one targeting the N protein for diagnostic purposes. For
sero-epidmiological studies, a test targeting the S protein is rec-
ommended. The added value to target the S protein is that the titres
are likely to better reflect protection against reinfection. In Table 2
we summarize the interpretation of diagnostic microbiological
Table 1




rRT-PCR Reference method, high sensitivity and specificity, compatibility with automation
and multipanels
Long TAT without automation
Nested PCR Increased sensitivity due to the added pre-amplification step Longer TAT and lower specificity due to the higher risk of
contamination
RT-LAMP Shorter TAT Possible slightly lower sensitivity
RT-iiPCR Possible slightly lower sensitivity
Gene expert Automation, high sensitivity and specificity, molecular rapid test High costs, limited number of samples per time
MNPs-based
methods
Increased rapidity, compatibility with automation
rRT-PCR, real-time reverse transcription polymerase chain reaction; RT-LAMP, reverse transcription loop-mediated isothermal amplification; RT-iiPCR, reverse transcription
insulated isothermal polymerase chain reaction; MNP, magnetic nanoparticle; TAT, turn-around-time.
Fig. 1. Kinetics of SARS-CoV-2 markers during infection and laboratory diagnosis. rRT-PCR, real-time reverse transcription polymerase chain reaction; RNA, ribonucleic acid; IgM,
immunoglobulin type M; IgG, immunoglobulin type G; Ab, antibodies.
Table 2
Clinical interpretation of microbiological diagnostic results
Symptoms rRT-PCR IgM IgG anti-S IgG anti-N Interpretation
þ/e þ e/þ e/þ þ/e Acute infection
þ d þ þ þ Recent infection
þ d þ þ þ Late onset infection
d d d þ þ/e Old infection
d d d d d Absence of infection
rRT-PCR, real-time reverse transcription polymerase chain reaction. þ/-: often
positive. -/þ: possible to be positive.
G. Caruana et al. / Clinical Microbiology and Infection 26 (2020) 1178e11821180tests according to the time of infection, the presence or absence of
symptoms and the type of diagnostic test used. Interestingly, the
high specificity of the S protein was corroborated by a study on
SARS-CoV-2 spike protein epitopes showing that, even considering
the homologies with SARS-CoV-1, the virus of COVID-19 exhibits
novel antibody epitopes [39]. This translates in the lack of efficacy
of SARS-CoV-1 antibodies against COVID-19 [40], but at the same
time it reinforces our trust in the specificity of the serological test
when targeting S proteins.
There are currently a huge number of tests on the market [21].
Ideally, only high-quality assays with sensitivity greater than 95%
and specificity superior or equal to 98% should be used. As well as
for NAATs, different platforms can be considered also for serological
tests. The lateral flow assays (LFAs) often exhibits a lower sensitivity
than the enzyme-linked immunosorbent assay (ELISA) and
chemiluminescent immune-assays (CLIAs) [41]. Among the
different LFAs, we identified the Dynamiker (Tianjin) as one of the
best, being both sensitive and specific (Coste et al., 2020, data not
shown, submitted). Nevertheless, we preferred ELISA and CLIA,
which enable larger series and less hands on time. In Lausanne, we
initially started on 14April using a ELISA-based assay (Epitope Di-
agnostics, USA) that was targeting the N protein; this ELISA
exhibited 96% of sensitivity on samples taken 15e30 days postinfection and a specificity of 100% on 450 samples taken before the
outbreak (Coste et al., 2020, data not shown, submitted). More
recently, we moved to CLIA. The Snibe run on Maglumy in-
struments (China) target the N protein, like the Roche CLIA, running
on Cobas instruments (Switzerland). Conversely, the Abbott test
running on the m2000 instruments (USA) and the Diasorin test
running on the Liaison instruments (Italy) both target the S protein.
As mentioned, median time for seroconversion is about
10e14 days [31e33], but early seroconversion has also been
documented at 3e5 days post infection [34]. Interestingly, the
appearance of IgM occurs at the same time as IgG but IgMs last for a
Table 3
Summary of indications for serological testing
Indication and usage Explanation
Help define the prognosis of a given subject Low IgG/IgM levels at 15 days post-infection might correlate with immunodeficit
Solve discrepancies between clinical
presentation and RT-PCR results
Despite high pre-test probability due to suspicious clinical presentation, molecular diagnosis might still results negative
in:
 Covid-19 complications (i.e. Kawasaki or GuillaineBarre syndrome, vasculitis, thrombo-embolic event)
 Late-onset disease (i.e. meningo-encephalitis or gastroenteritis)
Solve discrepancies between different molecular
tests
Different tests might be used, together with clinical presentation, as external gold standard in order to build the positive
group upon validation of a new molecular test
Retrospective diagnosis of SARS-CoV-2 infection SARS-CoV-2 infection potentially correlates with (transient?) acquired immunity
Sero-epidemiological studies To help assessing the magnitude of an ongoing outbreak (pandemic) and its spread rate
Support therapy perspectives Identify individuals with very high antibody titres that may be selected for blood donation to derive large amount of
immunoglobulins for passive immunotherapy treatment
G. Caruana et al. / Clinical Microbiology and Infection 26 (2020) 1178e1182 1181shorter time; thus, the main advantage to also test IgM is to assess
the timing of the infection.
The need of developing point-of-care devices to reduce TAT and
increase the number of daily tests have stimulated the research
towards faster and simpler kits. Numerous manufacturers quickly
developed rapid immunochromatographic point-of-care tests,
already available on the market [21].
At this point, data are being gathered on the diagnostic gain
obtained through these rapid kits, and further and more accurate
studies are warranted, which can define sensitivity and specificity
of the tests in relation with timing of infection and targeted
proteins.
Discussion
In a complex scenario such as the ongoing pandemic, not only
the diagnoses need to be timely and accurate, but laboratory testing
needs also to provide epidemiological information, in order to
assess the magnitude of the event and the spread rate. In this
setting, serological assays can become helpful both to complete the
epidemiological link when molecular diagnosis results are nega-
tive, and to alleviate the burden of laboratories implicated in mo-
lecular diagnosis [12]. In this way, a rapid point-of-care serological
assay, cheap and simple enough to be affordable by any hospital, if
used correctly (not at an early stage of disease), could allow
enlarging the spectrum of the tested population, especially among
those who did not develop enough symptoms to require hospital-
ization, hence molecular testing. At the same time, if used as an
asset for population screening at the right time and as adjunctive to
the reference method, the overall epidemiological information
gained could account for the sensitivity loss in early stages of
diagnosis. Indications for serological testing are summarized in
Table 3.
While serological assays can represent a useful epidemiolog-
ical asset, NAATs remains the reference standard for diagnosis
because of their high sensitivity even at early stages of the
disease.
Following the quantification of viral load over time and inte-
grating that with information on sample collection technique and
timing might be helpful to differentiate different stages of the
disease. Viral quantificationwill also provide information regarding
the value of testing different samples from different parts of the
body.
Owing to the main respiratory tropism of SARS-CoV-2, the best
samples (for sensitivity) come from the respiratory tract: in
particular, NP swabs showed higher and longer persisting viral
loads than OP swabs [42].
Because of the higher concentration of the virus in the lower
respiratory tract, it could be argued that the sensitivity of NP swabsis still not enough to avoid false-negative results. Samples from
lower respiratory tract, such as BAL or bronchial aspirates require
invasive procedures, not possible without intubation in subjects
already suffering from severe respiratory insufficiency.
Finally, the decision whether to trust or not a negative NP swab
should be always corroborated by the clinical presentation of the
patient [43] and, if possible, completed by serology testing. If a
strong clinical suspicion is present, repetition of the test is rec-
ommended. A newNP swab is the first option, since often the false-
negative NP test is due to inadequate sampling of only the distal
part of the nasal cavity. Repetition of the test with a lower respi-
ratory tract sample will be advisable for those patients admitted to
the hospital, hencewith heavier symptoms, but stable enough to be
submitted to invasive procedures. If the patient is asymptomatic
but still considered at risk of infection due to specific exposure,
investigating the serology between 10 and 15 days after the
exposure could help to document an asymptomatic infection.
Samples like blood and urine were found to be weakly to not
sensitive, while the virus was also found in faeces and perineal
swabs of patients with gastro-intestinal symptoms [44,45], indi-
cating another sample deserving further investigation.
Another consideration is whether the local (respiratory, gastro-
intestinal) microbiota play a role against the diffusion of the virus,
which, together with the immune system diversity, might
contribute to the variety of clinical presentations and affect
different viral concentrations [46,47].
Finally, considering this rapidly evolving pandemic and its
zoonotic outbreak, more knowledge needs to be gathered from
further studies in the diagnostic field, both investigating the spe-
cific features of this virus and novel diagnostic approaches, possibly
combining the molecular methods with the serologic ones in order
to booster sensitivity and specificity results. Despite the desperate
need to implement NAAT or serological test, the introduction of
these tests needs to be done with high quality criteria to assess the
performance of the tests in order to avoid a massive amount of false
positive and false negative results. To save time, the validation of
these tests should be centralized to reference laboratories and then
rapidly implemented in other laboratories upon validation of the
performance of the test.Transparency declaration
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